What psychological effects can occur from iatrogenic hyperthyroidism due to levothyroxine over‑replacement in a patient whose TSH fell from ~20 mIU/L to <0.2 mIU/L despite dose reductions?

Psychological Effects of Iatrogenic Hyperthyroidism from Levothyroxine Over-Replacement

Direct Neuropsychiatric Consequences of TSH Suppression

The prolonged TSH suppression this patient has experienced (TSH 0.02 → 0.17 over 5 months) creates a hypermetabolic state that manifests with significant psychological symptoms, even when patients appear clinically euthyroid. 1

Cognitive and Mood Disturbances

• Anxiety, irritability, and nervousness are cardinal psychological manifestations of iatrogenic hyperthyroidism, occurring even with subclinical TSH suppression (TSH 0.1–0.45 mIU/L) 2

• Insomnia and sleep disturbances result from the hypermetabolic state, creating a cycle of fatigue despite subjective restlessness 2

• Tremors and muscle weakness contribute to psychological distress by interfering with fine motor tasks and creating physical manifestations of internal anxiety 2

• Cognitive dysfunction and "brain fog" can paradoxically occur with overtreatment, particularly in elderly patients where excessive thyroid hormone creates fatigue rather than energy 1

Emotional Lability

• Mood instability and emotional dysregulation are common, with patients experiencing rapid shifts between irritability, anxiety, and depressive symptoms 2

• Heat intolerance and increased appetite create additional psychological stress as patients struggle with physical discomfort and potential weight changes 2

Silent Cardiovascular and Skeletal Risks Creating Psychological Burden

The Asymptomatic Danger

A critical finding from population studies is that patients with TSH suppression often feel subjectively well while incurring serious organ damage—this creates a dangerous disconnect between perceived health and actual risk. 1

• In a large cohort (N=6,884), low TSH (<0.21 mIU/L) showed no correlation with physical or psychological hyperthyroid symptoms, yet these patients faced 3–5 fold increased atrial fibrillation risk and significant bone loss 1

• This "silent" nature of TSH suppression means patients may dismiss their subtle symptoms (mild anxiety, sleep changes, tremor) as unrelated to medication, delaying recognition of overtreatment 1

Anxiety from Cardiovascular Awareness

• TSH suppression between 0.1–0.45 mIU/L increases atrial fibrillation risk 3–5 fold over 10 years, particularly in patients over 60 years 1

• Palpitations, tachycardia, and awareness of heartbeat create significant anxiety and hypervigilance about cardiac symptoms 2

• The knowledge of increased cardiovascular mortality (up to 2.2-fold for all-cause, 3-fold for cardiovascular death in those >60 years with TSH <0.5 mIU/L) can create anticipatory anxiety once patients become aware of their overtreatment 1

Bone Health Concerns

• For postmenopausal women, TSH suppression causes significant bone mineral density loss, creating anxiety about fracture risk and long-term skeletal health 1

• Women >65 years with TSH ≤0.1 mIU/L have markedly increased hip and spine fracture risk, and even TSH 0.1–0.45 mIU/L confers intermediate risk 1

Psychological Impact of Prolonged Dose Adjustment Period

Frustration with Treatment Resistance

This patient's 5-month struggle to normalize TSH despite incremental dose reductions creates significant psychological distress from treatment failure and loss of control. 1, 3

• The standard 6–8 week intervals between dose adjustments mean patients endure prolonged periods of symptoms while waiting for each titration to take effect 1

• Approximately 25% of patients on levothyroxine are unintentionally maintained with suppressed TSH, suggesting systemic challenges in achieving optimal dosing that can demoralize patients 1, 4

Medical Mistrust and Anxiety

• The initial rapid swing from severe hypothyroidism (TSH 20.9) to overtreatment (TSH 0.02) in just 5 weeks likely created anxiety about medication safety and provider competence 3

• Persistent overtreatment despite multiple dose reductions may generate fear that the medication cannot be properly controlled 1, 3

• Patients may develop hypervigilance about symptoms, interpreting every physical sensation as evidence of continued thyroid dysfunction 5

Quality of Life Impairment

Functional Impact

• Inadequate levothyroxine replacement (whether over- or under-treatment) is associated with poor health-related quality of life, particularly affecting physical and emotional domains 5

• The combination of anxiety, insomnia, tremor, and irritability significantly impairs work performance, social relationships, and daily functioning 2

• Headache and muscle spasm add to the physical burden of psychological symptoms 2

Comparison to Hypothyroid State

Paradoxically, some patients report that iatrogenic hyperthyroidism feels subjectively worse than their original hypothyroidism, because the anxiety and agitation are more distressing than fatigue. 1, 5

• Hypothyroid patients describe mental slowing and fatigue, which while unpleasant, may feel more manageable than the restless anxiety of overtreatment 1

• The hypermetabolic state creates a sense of being "revved up" that patients find exhausting rather than energizing 1

Risk of Psychiatric Misdiagnosis

Symptom Overlap with Primary Psychiatric Disorders

• Anxiety, insomnia, irritability, and mood lability from TSH suppression can be misattributed to primary anxiety disorders or bipolar spectrum illness 2

• Tremor and restlessness may be mistaken for akathisia or movement disorders 2

• If psychiatric medications are added without recognizing the iatrogenic hyperthyroidism, patients face polypharmacy risks and continued thyroid-related symptoms 6

Special Considerations for This Patient's Trajectory

The Whiplash Effect

This patient experienced a dramatic physiological whiplash—from severe hypothyroidism (TSH 20.9) to severe overtreatment (TSH 0.02) in 5 weeks, then persistent mild overtreatment (TSH 0.17) for 5 months. 3

• The initial jump to 200 mcg after medication non-adherence represents a full replacement dose that was excessive for someone whose thyroid may have partially recovered function 1, 3

• The brain and cardiovascular system have been subjected to rapid fluctuations in thyroid hormone availability, which may create more pronounced psychological symptoms than stable overtreatment 1

Medication Non-Adherence History

• The initial TSH of 20.9 resulted from forgetting medication, suggesting potential adherence challenges that may complicate ongoing management 6

• Pseudomalabsorption (intentional non-compliance) should be considered if TSH fails to normalize despite appropriate dose reductions, though this patient's pattern suggests true overtreatment 6

Management Implications for Psychological Symptoms

Immediate Dose Adjustment

• For TSH 0.17 mIU/L in a patient without thyroid cancer, reduce levothyroxine by 12.5–25 mcg immediately to allow TSH to rise toward the reference range (0.5–4.5 mIU/L) 1

• Recheck TSH and free T4 in 6–8 weeks after dose adjustment, as this represents the time needed to reach steady state 1, 3

Symptomatic Management

• Reassure the patient that psychological symptoms (anxiety, insomnia, irritability) will improve as TSH normalizes, typically within 6–8 weeks of appropriate dose adjustment 1, 2

• Beta-blockers may provide temporary relief of palpitations, tremor, and anxiety while waiting for thyroid levels to stabilize, though this is not routinely recommended 2

Monitoring for Complications

• Obtain ECG to screen for atrial fibrillation, especially given the prolonged TSH suppression and cardiovascular risk 1

• For postmenopausal women, consider bone density assessment (DXA scan) to evaluate fracture risk from the period of TSH suppression 1

• Ensure adequate calcium (1200 mg/day) and vitamin D (1000 units/day) intake to mitigate bone loss 1

Common Pitfalls in Managing Psychological Symptoms

• Failing to recognize that "feeling well" does not exclude serious overtreatment—patients may minimize symptoms while incurring cardiac and skeletal damage 1

• Attributing anxiety and mood symptoms to stress or primary psychiatric illness rather than recognizing iatrogenic hyperthyroidism 2

• Adjusting doses too frequently (before 6–8 weeks) prevents reaching steady state and prolongs the period of instability 1

• Underestimating the psychological impact of prolonged dose titration—patients need explicit counseling that normalization takes months, not weeks 1, 3